Clinical Trial Sponsors, Investigators and Institutional Review Boards Must Bare the Responsibility of Subject Safety

Events leading to the most recent high profile subject death in a gene therapy clinical trial are yet another indication of the lack of understanding, poor application of regulatory standards and in some cases lack of effective regulatory oversight in [...]